Cytochrome P450 2D6 (CYP2D6) is a critical pharmacogene involved in the metabolism of~
20% of commonly used drugs across a broad spectrum of medical disciplines including …

Importance Precise estimation of the drug metabolism capacity for individual patients is
crucial for adequate dose personalization. Objective To quantify the difference in the …

Genetic polymorphisms in cytochrome P450 (CYP) genes can result in altered metabolic
activity toward a plethora of clinically important medications. Thus, single nucleotide variants …

The American Psychiatric Association Practice Guideline for the Treatment of Patients With
Schizophrenia seeks to reduce these substantial psychosocial and public health …

The implementation of pharmacogenomic (PGx) testing in psychiatry remains modest, in part
due to divergent perceptions of the quality and completeness of the evidence base and …

Genes encoding cytochrome P450 enzymes (CYPs) are extremely polymorphic and multiple
CYP variants constitute clinically relevant biomarkers for the guidance of drug selection and …

Atomoxetine is a nonstimulant medication used to treat attention‐deficit/hyperactivity
disorder (ADHD). Cytochrome P450 (CYP) 2D6 polymorphisms influence the metabolism of …

Interindividual variability in drug disposition is a major cause of lack of efficacy and adverse
effects of drug therapies. The majority of hepatically cleared drugs are metabolized by …

Extensive migration has led to the necessity of knowledge regarding the treatment of
migrants with different ethnical backgrounds. This is especially relevant for pharmacological …

hydroxytryptamine type 3 (5-HT 3) receptor antagonists are used in the prevention of
chemotherapy-induced, radiation-induced and postoperative nausea and vomiting. CYP2D6 …